Genentech Launches New Oncology Product: Gavreto
… Genentech expands oncology product portfolio

New Genentech Oncology Drug Gavreto Approved by FDA

Gavreto is the sixth FDA-approved lung cancer therapy in the Roche portfolio

Brand marketing and market access strategy for Gavreto

The new product’s review was given a high priority by the FDA so the decision to approve it would be made sooner

More indications for Gavreto may follow

Blueprint Medicines has distinctive expertise in protein kinases

Genentech is a wholly-owned business unit of Roche

Authentic, fact-based healthcare content marketing writing for medical, business, academic, patient and consumer audiences

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store